Allopurinol induced Stevens-Johnson syndrome: A case report

Journal of the Pakistan Medical Association

Volumn 50, Issue 6, 2000, Pages 207-209

  Bashir, Shahida ^a   Shah, Syed Mahmood Ali ^a   Babar, Ijlal ^b  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; AZAPROPAZONE; DICLOFENAC; IBUPROFEN; INFUSION FLUID; LOXOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; HUMAN; NUTRITIONAL SUPPORT; PRESCRIPTION; PROVOCATION TEST; STEVENS JOHNSON SYNDROME;

AGED; ALLOPURINOL; EMERGENCIES; ENZYME INHIBITORS; FEMALE; HUMANS; STEVENS-JOHNSON SYNDROME;

EID: 0343441521     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bigby M, Jick S. Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA, 1986;256:3358-63.
2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis. N. Eng. J. Med., 1995;333:1600-07.
3. Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N. Engl. J. Med., 1994;331:1272-85.
4. Yetiv JZ, Bianchine JR, Owen JA Jr. Etiologic factors of the Stevens-Johnson syndrome. South Med. J , 1980;73:599-602.
5. Chan HL, Stern RS, Arndt KA, et al. The incidence of Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis A population-based study with particular reference to reactions caused by drugs among outpatients; Arch. Dermatol., 1990;126:43-47.
6. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch. Dermatol., 1987;123:1160-65.
7. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal Necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch. Dermatol., 1991;127:839-42.
8. Roujeau JC, Guillame JC, Fahre JP. Toxic Epidermal Necrolysis (Lyell Syndrome); Incidence and drug etiology in France, 1981-1985. Arch. Dermatol., 1990;126:37-42.
9. Merot Y, Gravellese E, Guillen FJ, et al. Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis : report of a case. Arch. Dermatol., 1986;122:455-58.
10. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch. Dermatol., 1993;129:466-68.
11. Stampien TM, Schwartz RA Erythema multiforme. Amer. Fam. Phys., 1992;46:1171-76.
12. Lehrer Bell KA, Kirsner RS, Tallman PG, et al. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate impregnated dressings. Arch. Dermatology, 1998;134:877-79.
13. Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest, 1990;98:331-36.
14. Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br. Med. J., 1985;290:1969-70.
15. Pennell DJ, Nunan To, O-Doherty MJ, et al. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet, 1984;1:463.
16. Trisha G. Drug prescription and Self-Medication in India: An Exploratory Survey. Soc. Sci. and Med., 1987;25:307-18.
17. Gonzalez U, Reyes E, Kershenovich J, et al. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev. Invest. Clin., 1995;4:7409-13.
18. Huang RY, Liu-HN, Wong CK. Stevens-Johnson syndrome:a review of 42 cases. Chung Hua I Hsueh Tsa Chieh Taipei, 1993;51:225-30.
19. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review Ann Pharmacother., 1993;27:337-43.
20. Stratigos JD, Bartsokas SK, Capetanikas J. Further experiences of toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives. Br. J. Dermatol., 1972;86:564-67.